View by Specialty

Trending

Drinking more coffee and tea lowers the risk for developng multiple cardiometabolic disorders.
September 17, 2024
3 min read
Save

Drinking moderate amounts of caffeine may cut risk for multiple cardiometabolic diseases

Optometry News

SPONSORED CONTENT
Save
SPONSORED CONTENT
July 29, 2024
2 min read
Save

Early vision loss linked to challenges judging auditory distances

Early vision loss linked to challenges judging auditory distances

Early-onset vision loss may be associated with difficulty judging auditory distance, particularly close and middle distances, according to research published in Optometry and Vision Science.

SPONSORED CONTENT
July 29, 2024
2 min watch
Save

VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME

VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME

In this Healio Video Perspective from the ASRS meeting, Diana V. Do, MD, FASRS, of Byers Eye Institute discusses data from the PHOTON trial investigating aflibercept 8 mg and aflibercept 2 mg for the treatment of diabetic macular edema.

Trending

Drinking more coffee and tea lowers the risk for developng multiple cardiometabolic disorders.
September 17, 2024
3 min read
Save

Drinking moderate amounts of caffeine may cut risk for multiple cardiometabolic diseases

SPONSORED CONTENT
July 29, 2024
3 min watch
Save

VIDEO: Macular neovascularization did not impact reduction in GA growth in GATHER trials

VIDEO: Macular neovascularization did not impact reduction in GA growth in GATHER trials

In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.

SPONSORED CONTENT
July 29, 2024
2 min read
Save

DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema

DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema

Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.

SPONSORED CONTENT
July 28, 2024
7 min watch
Save

VIDEO: Preserving domain authority key for Google’s algorithm

VIDEO: Preserving domain authority key for Google’s algorithm

In this Healio Video Perspective, Cynthia Matossian, MD, FACS, and David Evans, PhD, MBA, share pearls on how to successfully navigate Google’s algorithm when marketing an ophthalmology practice.

SPONSORED CONTENT
July 27, 2024
4 min watch
Save

VIDEO: Maintain a practice website’s URLs to protect online ranking

VIDEO: Maintain a practice website’s URLs to protect online ranking

In this Healio Video Perspective, Cynthia Matossian, MD, FACS, and David Evans, PhD, MBA, discuss how to revise or update a practice’s website without affecting its online ranking.

SPONSORED CONTENT
July 26, 2024
1 min read
Save

Dropless vitrectomy for vitreous hemorrhage controls intraocular inflammation

Dropless vitrectomy for vitreous hemorrhage controls intraocular inflammation

A form of dropless vitrectomy helped control intraocular inflammation and prevent infection after surgery for vitreous hemorrhage secondary to proliferative diabetic retinopathy, according to a study.

SPONSORED CONTENT
July 26, 2024
5 min read
Save

Q&A: Many patients unaware of dry eye, treatment options

Q&A: Many patients unaware of dry eye, treatment options

July is Dry Eye Awareness Month, but educating patients about symptoms and treatment is critical throughout the year, especially in light of recent data that show many American adults do not know relief is possible.

SPONSORED CONTENT
July 26, 2024
3 min watch
Save

VIDEO: Aflibercept 8 mg shows comparable safety to aflibercept 2 mg at 96 weeks

VIDEO: Aflibercept 8 mg shows comparable safety to aflibercept 2 mg at 96 weeks

In this Healio Video Perspective from the ASRS meeting, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston discusses 96-week safety and tolerability data for aflibercept 8 mg.

SPONSORED CONTENT
July 26, 2024
1 min read
Save

Study: 0.01% atropine drops slow myopia progression, do not interfere with exotropia

Study: 0.01% atropine drops slow myopia progression, do not interfere with exotropia

Low-dose 0.01% atropine eye drops safely slowed myopia progression in children with myopia and intermittent exotropia, with some compromise on accommodative amplitude.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails